This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Investment Ideas From Wall Street: Jan. 24

5) Time for a Biotech Reassessment

Is it time for this sector too cool off a bit after a strong run up? Drug development and sales is key in determining the rise and fall of an individual biotech stock, but JP Morgan is taking "a more cautious view" on performance in the overall sector for 2012. Given that these stocks got a jumpstart at the beginning of the year, JP Morgan says, it is "less willing to broadly chase the sector at current levels.''

The companies getting moved to Neutral from Overweight are Amgen (AMGN - Get Report), ViroPharma (VPHM) and Acorda (ACOR). Meanwhile, JP Morgan recommends putting profits into Gilead Sciences (GILD) or Celgene (CELG) in the large-cap sector, or InterMune (ITMN), Medivation (MDVN) or Alexion (ALXN)in the mid-cap sector.

Biotech stocks on the Nasdaq are up 8.3% so far this year, while the New York Stock Exchange's biotechnology index BTK is up 13.8%. Among the factors that have boosted the broader market are Bristol-Meyers Squibb's (BMY) acquisition of Inhibitex (INHX) and drug launches by Dendreon (DNDN) and Regeneron Pharmaceuticals (REGN).

Amgen shares, up 25% in the last two months, have beaten both the S&P 500 index and the broader biotech gains on the Nasdaq. While JP Morgan raised its December 2012 price target on Amgen to $75 from $70 a share, it says that the stock isn't compelling right now.

"A restructuring or an increase in the payout ratio seems unlikely near term with the new management team," writes the analysts. "We don't think there are a lot of efficiency gains to be made going forward, especially with Amgen's consistent focus on innovation." The firm's management team is expected to be in place by mid-year.

ViroPharm and Acorda, similarly, have outperformed the broader sector recently, and may have limited upside. ViroPharm shares have already seen a run up after the company announced late 2011 that its exclusivity on Vancocin had been extended for three years. A sustained rally in Acorda stocks is uncertain given that it may already reflect the market's optimism toward the company's key drug labels and trials. "With the initial patient backlog now fully cleared for Ampyra, and a focus today more on a DTC type of commercial effect, we see more slow and steady market share gains ahead for Ampyra rather than an inflection point," writes JP Morgan.

-- Written by Chao Deng in New York.

>To contact the writer of this article, click here: Chao Deng.

>To follow the writer on Twitter, go to: @chao_deng

>To submit a news tip, send an email to:
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $160.56 -0.27%
TIF $72.04 -1.80%
VMW $57.54 -1.62%
AAPL $95.03 -2.90%
FB $116.73 7.20%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs